The slide presentation to be used during the conference call referenced in the press release is attached hereto as Exhibit 99.2 and incorporated herein by reference. The information contained herein, including the exhibits attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth b…

The slide presentation to be used during the conference call referenced in the press release is attached hereto as Exhibit 99.2 and incorporated herein by reference. The information contained herein, including the exhibits attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth b…

Other Events. On April 7, 2026 , the Company issued a press release announcing topline efficacy and safety results from its Phase 2b CEDAR study of brensocatib in patients with HS. The CEDAR study was a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of brensocatib in adults with moderate to severe HS. The study enrolled 214 patients at 72 sites globally. In the study, participants were randomized 1:1:1 to receive brensocatib 10 mg, brensocatib 40 mg, or…

Other Events. On March 23, 2026 , the Company issued a press release announcing positive topline results from the ENCORE Study. Topline efficacy results from the ENCORE Study are as follows: ARIKAYCE 590 mg plus azithromycin 250 mg + ethambutol 15 mg/kg once-daily (N=213) Placebo plus azithromycin 250 mg + ethambutol 15 mg/kg once-daily (N=212) Treatment difference, p-value Primary Endpoint Change from Baseline in Respiratory Symptom Score at Month 13 17.77 points 14.66 points 3.11 points, p=…

Class II director and chair of the Audit Committee — David W.J. McGirr: Mr. McGirr will not stand for re-election to the Board upon the expiration of his current term.

The slide presentation to be used during the conference call referenced in the press release is attached hereto as Exhibit 99.2 and incorporated herein by reference. The information contained herein, including the exhibits attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth b…

Other Events. On December 17, 2025 , the Company issued a press release announcing topline efficacy and safety results from the Phase 2b BiRCh study of brensocatib for patients with CRSsNP. The BiRCh study was a randomized, double-blind, parallel-group, placebo-controlled, multicenter study to evaluate the efficacy and safety of brensocatib compared to placebo. The study was conducted at 104 sites globally, and a total of 288 patients were randomized 1:1:1 to receive either brensocatib 10 mg…

Regulation FD Disclosure. On December 17, 2025 , Insmed Incorporated (the “Company”) issued a press release announcing topline efficacy and safety results from the Phase 2b BiRCh study of brensocatib in patients with chronic rhinosinusitis without nasal polyps (“CRSsNP”) and the acquisition of INS1148, an investigational monoclonal antibody that the Company plans to develop for respiratory and immunological and inflammatory diseases with high unmet need. A copy of the press release is attache…

and is incorporated herein by reference. The slide presentation to be used during the conference call referenced in the press release is furnished herewith as Exhibit 99.2. The information contained herein, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, ex…

Regulation FD Disclosure. On August 12 , 2025, Insmed Incorporated (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (“FDA”) has approved BRINSUPRI™ (brensocatib 25 mg and 10 mg tablets), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis in adults and children 12 years and older. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The Company will h…

and is incorporated herein by reference. The slide presentation to be used during the conference call referenced in the press release is furnished herewith as Exhibit 99.2. The information contained herein, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, ex…

Other Events. On June 11 , 2025, Insmed Incorporated (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC and Leerink Partners LLC as representatives of the several underwriters (the “Underwriters”), pursuant to which, subject to satisfaction of the conditions set forth therein, the Company has agreed to sell to the Underwriters, and the Underwriters have agreed to purchase from the Company, 7,812,500 shares (the “Firm Shares”) of…

Other Events. On June 10, 2025, the Company announced positive topline results from its Phase 2b TPIP PAH study, a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of TPIP administered once daily in patients with PAH (World Health Organization Group 1). The study met its primary endpoint and all secondary efficacy endpoints. For the primary endpoint, the placebo-adjusted reduction from baseline in pulmonary vascular resistance (“PVR”) was 35% with Least Sq…

Other Events On June 6, 2025 (the “Redemption Date”), Insmed Incorporated (the “Company”) completed its previously announced redemption of all of the aggregate principal amount outstanding of its 0.75% Convertible Senior Notes due 2028 (the “Notes”). Outstanding Notes in the aggregate principal amount of $1,965,204.69 that had not already been converted by holders thereof were redeemed for cash at a redemption price equal to 100% of the principal amount of such Notes, plus accrued and unpaid…

The filing is about the approval of an amendment to a compensatory incentive plan, not a management change.

and is incorporated herein by reference. The slide presentation to be used during the conference call referenced in the press release is furnished herewith as Exhibit 99.2. The information contained herein, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, ex…

Other Events On April 24, 2025, Insmed Incorporated (the “Company”) issued a press release, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference, announcing that it has called all $569.5 million aggregate principal amount of its remaining outstanding 0.75% Convertible Senior Notes due 2028 (the “Notes”) for redemption. The redemption will be effected pursuant to the terms of the Indenture, dated as of January 26, 2018, as supplemented by the Second Supplemen…

Chief Commercial Officer — J. Drayton Wise: Mr. Wise resigned for personal and medical reasons.

The slide presentation to be used during the conference call referenced in the press release is attached hereto as Exhibit 99.2 and incorporated herein by reference. The information contained herein, including the exhibits attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 , as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth…

Director — Alfred Altomari: Mr. Altomari will not stand for re-election to the Board upon the expiration of his current term.

Termination of a Material Definitive Agreement. As previously disclosed, on February 22, 2024, Insmed Incorporated (the “Company”) entered into a Sales Agreement (the “Agreement”) with Leerink Partners LLC, as agent (“Leerink”), under which the Company may offer and sell its common stock, par value $0.01 per share, from time to time having an aggregate offering price of up to $500,000,000 during the term of the Agreement through Leerink, acting as agent. On November 18, 2024, the Company term…

The information contained herein, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under

Entry into a Material Definitive Agreement. On October 31, 2024, Insmed Incorporated (the “Company”) entered into an Amended and Restated Loan Agreement with BioPharma Credit PLC (the “Collateral Agent”), BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP, which are funds managed by Pharmakon Advisors, LP (collectively, “Pharmakon”), and the guarantors party to such agreement (the “A&R Loan Agreement”). The A&R Loan Agreement amends and restates the Company’s prior Loan A…

Other Events On August 9, 2024 (the “Redemption Date”), Insmed Incorporated (the “Company”) completed its previously announced redemption of all of the aggregate principal amount outstanding of its 1.75% Convertible Senior Notes due 2025 (the “Notes”). Outstanding Notes in the aggregate principal amount of $198,000 that had not already been converted by holders thereof were redeemed for cash at a redemption price equal to 100% of the principal amount of such Notes, plus accrued and unpaid int…